Drug

medicine

DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit

DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a precision medicine focused session at the fourth annual Dermatology Drug Development Summit. Held virtually this year, the Dermatology Drug Development Summit is the only industry-focused meeting dedicated to innovating, accelerating, and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need. 

The session, titled, “Stickering it to Skin Disease: The Drive for Precision and Personalized Dermatology,” presented by Michael D. Howell, PhD, Chief Scientific Officer of DermTech, explored the current approaches to precision medicine in dermatology and the integration of precision medicine and biomarker approaches in clinical trials. Howell reviewed DermTech’s proprietary Smart Sticker platform and its use in early detection of skin cancers including cutaneous melanoma. Howell also discussed how non-invasive skin sampling can enhance precision medicine by detecting genomic and proteomic changes in the skin without the need for a skin biopsy. Finally, Howell discussed how the expanded use of DermTech’s breakthrough tool can guide personalized approaches to disease diagnosis and intervention.

The presentation is available for viewing here.

“The Dermatology Drug Development Summit brings together leaders in academia, government, and industry with a goal of driving innovative medicine in dermatology. The DermTech Smart Sticker is an innovative platform that non-invasively assesses genomic and proteomic changes in the skin before those changes can be visually detected. With more than 3,000 potentially identifiable dermatological diseases and an ever increasing armamentarium of therapies, the Smart Sticker technology enables innovative approaches to precision and personalized dermatology,” commented Howell.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the Smart Sticker platform, and the market opportunity therefor. These forward-looking statements involve

Read More
medicine

EU fines drug makers for keeping cheap medicine off market

The European Union has fined two pharmaceutical companies for colluding to keep a cheap alternative to a sleep disorder medicine off the market for their profit and at the expense of patients

The European Union has fined two pharmaceutical companies for colluding to keep a cheap alternative to a sleep disorder medicine off the market for their profit and at the expense of patients.

EU antitrust commissioner, Margrethe Vestager, said that Teva pharmaceuticals and Cephalon, a company it later acquired, must pay 60.5 million euros ($72 million) for agreeing between themselves to delay for years the launch of Teva’s cheaper version of Cephalon’s blockbuster Modafinil. In return for the delay, Teva got beneficial side deals and some payments.

Modafinil treats excessive daytime sleepiness and under the brand name Provigil it accounted for more than 40% of Cephalon’s turnover. A cheap alternative would have had a serious impact on the company, and the EU argued that Cephalon enticed Teva in 2005 to stay out of its market. In 2011, Teva acquired Cephalon.

Teva did not immediately respond to a request for comment.

Source Article

Read More
medicine

Jewish psychedelics advocate working to turn drug into legal medicine

When Rick Doblin was in his early 20s, he had a dream in which he was escorted back in time to witness a Holocaust survivor’s narrow escape from the Nazis.

In his mind, Doblin traveled to Eastern Europe to witness thousands of Jews lined up alongside a mass grave as the gunners open fire, toppling the bodies into the earth. The man spends three days alive underground before emerging and fleeing to the woods, where he survives the war in hiding.

The man then tells Doblin that he survived this horror only to deliver a message that Doblin should devote his life to promoting psychedelics as a cure for human ills and an insurance policy against another Holocaust. Then he expires.

Doblin took the advice to heart. For much of the next four decades, he waged an often frustrating battle to get public health authorities to recognize the value of psychedelics, the perception-shifting compounds popularized in the 1960s that have been a source of both fear and fascination ever since.

“I’ve always felt that the response to the Holocaust is helping people realize our common humanity,” Doblin said. “And that there are many ways to do that, and psychedelic mystical experiences are one of the ways. And so I felt like what I’m doing is to try to prevent another Holocaust and that that’s the deepest motivation.”

In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value and a high potential for abuse. But a growing body of research has shown their efficacy for a range of mental illnesses that have proven resistant to other treatments, including post-traumatic stress disorder, addiction, depression and anxiety. Research underway at Johns Hopkins and New York University is also investigating whether psychedelics can be of use in a wider array of applications, including one study on whether the drugs can induce spiritual experiences among religious clergy.

Doblin has funded some of this research as the founder of the Multidisciplinary Association for Psychedelic Studies, a nonprofit he runs from his home here in suburban Boston. And after years of effort and $100 million raised, he now stands on the cusp of a major victory.

In late October, Doblin received preliminary results from a MAPS-funded phase 3 study of the effects of MDMA — better known as the club drug Ecstasy — on PTSD. Phase 3 trials are typically the final hurdle before the Food and Drug Administration authorizes a drug for public use. Those preliminary results showed MDMA surpassed the FDA’s threshold for statistical significance in treating PTSD.

A formal scientific paper is due early next year and Doblin expects government authorization for prescription use will eventually follow. If it does, it would be the first time the federal government has ever approved a psychedelic to assist in psychotherapy.

“It’s enormously satisfying because it was something

Read More
medicine

COVID-19 and aspirin: Can this common drug in your medicine cabinet reduce your risk of dying from COVID? Here’s what a new study found

At least 29 million Americans take low-dose aspirin every day in hopes of preventing a heart attack or stroke.

Now, a new University of Maryland study found that hospitalized COVID-19 patients, who were taking a daily 81-milligram dose of aspirin, had a significantly lower risk of complications than those not taking aspirin.

“Forty percent across the board did not require a ventilator, did not need to go to the ICU,” explained Dr. Michael Daignault, an ER physician at Providence St. Joseph Hospital.

MORE: Moderna’s COVID-19 vaccine could be up to 94.5% effective

Dr. Daignault says aspirin’s ability to reduce blood clots may be the key.

“We know that aside from being a respiratory virus, that COVID-19 at the local organ level causes a lot of mini clots,” Dr. Daignault said.

Clotting and inflammation is what sends many patients into the ICU.

So during this pandemic, should everyone be taking daily baby aspirin? Dr. Daignault says this was a small correlation study and without more research, he would not advise it.

“It’s hard to say if they got better because of the aspirin specifically or because of other reasons,” Dr. Daignault explained.

MORE: People with blood type O may have lower risk of COVID-19, studies suggest

A Harvard study found more than six million Americans are taking aspirin without a doctor’s advice or knowledge. Experts say for people who don’t have severe cardiovascular issues, the risks may outweigh the potential benefits.

“Aspirin can raise your risk of having gastritis or irritation of your stomach lining or a ulcer or an upper gastrointestinal bleed,” Dr. Daignault said.

If you’re thinking about taking a daily baby aspirin for any health reason, it’s important that you discuss this with your doctor first.

“Aspirin is cheap, it’s widely available, and it could be a potential game changer, but we definitely need more perspective or robust studies,” Dr. Daignault said.

RELATED | Which masks protect those around you best? Researchers weigh in

Copyright © 2020 KABC-TV. All Rights Reserved.

Source Article

Read More
medicine

Medicine: State could be affordable drug maker

As the leader of Washington #insulin4all and a board member of Health Care for All Washington, I am working with our legislators to introduce a bill that will also allow our state to create its own generic prescription drugs.

Washington would contract directly with generic drug manufacturers to produce medicine for state residents. The public production of medicines like insulin could lower prices and increase access to life-saving drugs.

Although it may sound radical for states to make medicine, it’s actually not that unusual. California’s Department of Public Health has manufactured the only treatment for infant botulism since 2003, and in Massachusetts the state-owned non-profit MassBiologics has produced vaccines for over 100 years.

Last year, I testified next to an 8-year-old afraid of rationing insulin as we spoke in support of copay caps on insulin in Washington. I became friends with a mother whose daughter moved abroad due to the cost of medicine.

Washington has an opportunity to end all that doubt and misery while creating jobs in the pharmaceutical industry and generating revenue for the state.

On World Diabetes Day, November 14, please take the time to contact your representatives in support of this transformative step.

Source Article

Read More
medicine

Latest Update on Drug (Medicine) Dispenser Market by Emerging Trends, Share, Growth Rate, Opportunities And Market Forecast To 2021

The MarketWatch News Department was not involved in the creation of this content.

New York, United States, Tue, 10 Nov 2020 09:12:58 / Comserve Inc. / — Global drug (medicine) dispenser market is expected to register a robust CAGR over the forecast period. Moreover, the global drug (medicine) dispenser market is expected to reach at notable revenue by the end of 2021.

The global drug (medicine) dispenser market is segmented into application such as hospitals, pharmacies and homecare. Among these segments, homecare segment is expected to grow at maximum pace during the forecast period. The rise of the homecare segment is backed by the increasing demand for drug (medicine) dispenser by patients who have to response to drugs on daily basis and especially by patients who have memory deficiencies. However, it can be used in hospitals and pharmacies also to reduce chances of medication error.

Global drug (medicine) dispenser market is expected to register a robust CAGR over the forecast period. Moreover, the global drug (medicine) dispenser market is expected to reach at notable revenue by the end of 2021. Factor such as technological advancements in medical devices and increasing geriatric population across the globe are expected to be the dynamic factors behind the growth of this segment during the forecast period.

The North America segment by region accounted for major share of global drug (medicine) dispenser market in 2015.Moreover, North America drug (Medicine) dispenser is poised to display substantial growth during the forecast period owing to a number of factors such as swelled disposable income, high spending on healthcare and increasing adoption of advanced medical devices in this region.

Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-73

Increased Geriatric Population

Factors such as increasing older population and rising incidence of age-related memory weakness are anticipated to fuel the demand for drug (medicine) dispenser over the forecast period. Furthermore, drug (medicine) dispenser helps aged people to maintain their regular medication and avoid any medication error. This factor is envisioned to escalate the growth of Drug (Dispenser) Market in Future.

Technological Advancements in Medical Devices

Demand for automated medication dispensing system is increasing due to its advantages such as prevention of medication error, easy controlling and better customization. Additionally, swift advancements in healthcare technologies and concerns regarding patient’s health and medication in hospitals is also increasing the demand for drug (medicine) dispenser in hospitals which in turn likely to foster the growth of global drug (medicine) dispenser market over the forecast period.

Although, high repair and maintenance cost of advanced medication dispenser and slow adoption rate in under developed countries are some of the factors that are likely to obstruct the growth of the drug (medicine) dispenser market in the near future.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/global-drug-medicine-dispenser-market-analysis-opportunity-outlook-2021/73

This report also provides the existing competitive scenario of some of

Read More
medicine

Drug (Medicine) Dispenser Market Evolving Technology, Segmentation and Industry Analysis 2015 to 2021

The MarketWatch News Department was not involved in the creation of this content.

New York, United States, Sat, 31 Oct 2020 08:34:44 / Comserve Inc. / — Global drug (medicine) dispenser market is expected to register a robust CAGR over the forecast period. Moreover, the global drug (medicine) dispensermarket is expected to reach at notable revenue by the end of 2021

The global drug (medicine) dispensermarket is segmented into application such as hospitals, pharmacies and homecare. Among these segments, homecare segment is expected to grow at maximum pace during the forecast period. The rise of the homecare segment is backed by the increasing demand for drug (medicine) dispenserby patients who have to response to drugs on daily basis and especially by patientswho have memory deficiencies. However, it can be used in hospitals and pharmacies also to reduce chances of medication error.

Global drug (medicine) dispenser market is expected to register a robust CAGR over the forecast period. Moreover, the global drug (medicine) dispensermarket is expected to reach at notable revenue by the end of 2021.Factor such as technological advancements in medical devices and increasing geriatric population across the globe are expected to be the dynamic factors behind the growth of this segment during the forecast period.

The North America segment by region accounted for major share of global drug (medicine) dispenser marketin 2015.Moreover, North America drug (Medicine) dispenser is poised to display substantial growth during the forecast period owing to a number of factors such as swelled disposable income, high spending on healthcare and increasing adoption of advanced medical devices in this region.

Download Sample of This Strategic Report @https://www.researchnester.com/sample-request-73

Increased Geriatric Population

Factors such as increasing older population and rising incidence of age-related memory weaknessare anticipated to fuel the demand for drug (medicine) dispenser over the forecast period.Furthermore, drug (medicine) dispenserhelps aged people to maintain their regular medication and avoid any medication error.This factor is envisioned to escalate the growth of Drug (Dispenser) Market in Future.

Technological Advancements in Medical Devices

Demand for automated medication dispensing systemis increasing due to its advantages such as prevention ofmedication error, easy controlling and better customization.Additionally, swift advancements in healthcare technologies and concerns regarding patient’s health and medication in hospitals is also increasing the demand for drug (medicine) dispenser in hospitals which in turn likely to foster the growth of global drug (medicine) dispenser market over the forecast period.

Although,high repair and maintenance cost of advanced medication dispenserand slow adoption rate in under developed countries are some of the factors that are likely to obstruct the growth of the drug (medicine) dispenser market in the near future.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Curious about this latest version of report? Obtain Report Details @https://www.researchnester.com/reports/global-drug-medicine-dispenser-market-analysis-opportunity-outlook-2021/73

This report also provides the existing competitive scenario of some of the key players of the global drug (medicine) dispensermarket which includes company profiling ofKoninklijke Philips N.V.,

Read More
health

Oregon Measure 110 on drug recovery treatment: live results

  • Measure 110 in Oregon would provide drug recovery services partially funded through marijuana taxes. 
  • Polls in Oregon closed at 11 p.m. ET.
  • The measure would also reclassify the penalties for specified drugs.
  • Insider will have live results on the propositions as soon as they come in.
  • Visit Business Insider’s homepage for more stories.

Polls in Oregon closed at 11 p.m. ET.

Oregon’s 2020 ballot includes Measure 110, which would provide statewide drug recovery services partially funded by marijuana taxes and would reclassify the penalties for certain drugs.

The text for Oregon Measure 110 reads as follows:

Summary

Measure mandates establishment/ funding of “addiction recovery centers” (centers) within each existing coordinated care organization service area by October 1, 2021; centers provide drug users with triage, health assessments, treatment, recovery services. To fund centers, measure dedicates all marijuana tax revenue above $11,250,000 quarterly, legislative appropriations, and any savings from reductions in arrests, incarceration, supervision resulting from the measure. Reduces marijuana tax revenue for other uses. Measure reclassifies personal non-commercial possession of certain drugs under specified amount from misdemeanor or felony (depending on person’s criminal history) to Class E violation subject to either $100 fine or a completed health assessment by center. Oregon Health Authority establishes council to distribute funds/ oversee implementation of centers. Secretary of State audits biennially. Other provisions.

Result of “Yes” Vote

“Yes” vote provides addiction recovery centers/services; marijuana taxes partially finance (reduces revenues for other purposes); reclassifies possession of specified drugs, reduces penalties; requires audits.

Result of “No” Vote

“No” vote rejects requiring addiction recovery centers/services; retains current marijuana tax revenue uses; maintains current classifications/ penalties for possession of drugs.

Source Article

Read More
health

Type 2 diabetes drug recalled over concerns medication contaminated with possible carcinogen

Metformin, a medication to treat type 2 diabetes, is facing a recall over concerns it has been contaminated with a possible cancer-causing substance. 

Nostrum Laboratories Inc., the maker of Metformin, announced it is voluntarily recalling two lots of the medication – Metformin HCl Extended-Release Tablets, USP 750 mg – because the lots have been found to contain above-acceptable limits of nitrosamine, also known as NDMA, a “probable human carcinogen,” per the recall announcement posted to the U.S. Food and Drug Administration’s (FDA) website on Monday. 

This isn’t the first time excess levels of NDMA in medications have prompted recalls. In the past, certain blood pressure and heartburn medications have been affected.

This isn’t the first time excess levels of NDMA in medications have prompted recalls. In the past, certain blood pressure and heartburn medications have been affected.
(iStock)

“NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products and vegetables,” per the announcement. 

No adverse events related to the recalled medications have been reported to date, the company said. 

METHOD HAND SOAP RECALLED OVER BACTERIA CONTAMINATION CONCERNS 

The affected medications are packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01, per the announcement on the FDA’s website. Lot numbers are MET200101 and MET200301. Both lots have an expiration date of May 2022. 

“The product can be identified as an off-white oblong tablet debossed with ‘NM7.’ Metformin HCl Extended-Release Tablets, USP 750 mg was distributed nationwide to wholesalers,” per the announcement. 

COLORADO HIKER WITH CORONAVIRUS-LIKE SYMPTOMS FOUND TO HAVE RARE, POSSIBLY LIFE-THREATENING DISEASE

“Nostrum Laboratories Inc. is notifying its distributors by letter and is arranging for return of all recalled products. Pharmacies that have Metformin HCl Extended-Release Tablets, USP 750 mg, which is being recalled, should return to place of purchase. Consumers should consult a health care professional to obtain a replacement or a different treatment option,” the announcement reads. “It could be dangerous for patients with type 2 diabetes to stop taking their Metformin without first talking to their health care professional. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking this drug product.”

COTTONELLE FLUSHABLE WIPES RECALLED OVER BACTERIA CONCERNS

Consumers with additional questions can contact Nostrum Laboratories Inc. Medical Affairs at 816-308-4941 or email [email protected] 

This isn’t the first time excess levels of NDMA in medications have prompted recalls. In the past, certain blood pressure and heartburn medications have been affected.

Source Article

Read More
health

U.S. Experts to Review Biogen Drug That Could Be First New Alzheimer’s Treatment in Decades | Top News

(Reuters) – U.S. health experts this week will decide whether to recommend approval for Biogen Inc’s

Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works.

In a field littered with unrelenting failure, Biogen believes in aducanumab it has the first drug that can treat an underlying cause, and therefore slow progression, of Alzheimer’s. But its path to approval has been anything but smooth or assured.

Biogen abruptly ended clinical trials of aducanumab last year after an early look at trial results showed it was not effective. Last October, the company shocked many Alzheimer’s experts by reversing course, saying that a new analysis showed aducanumab could help patients with early-stage disease preserve their ability to function independently for longer. In July, Biogen filed for approval from the Food and Drug Administration.

Now the agency faces tremendous pressure to approve a treatment option for millions of Americans suffering from Alzheimer’s and the millions more expected to face it in coming years.

Patient advocates say the need for a new Alzheimer’s treatment that could help people remain independent is heightened by the coronavirus pandemic, which has killed more than 229,000 people in the United States, including tens of thousands of seniors in nursing homes.

“The pandemic came and it changed everything,” said Russ Paulsen, chief operating officer at patient advocacy group UsAgainstAlzheimer’s. “We need something to keep people out of nursing homes.”

A committee of outside advisers to the FDA will discuss aducanumab on Nov. 6. The agency’s final decision is expected by March. European health regulators have also accepted the drug for review.

Charles Flagg, a 79-year-old retired minister from Jamestown, Rhode Island, had been enrolled for years in a trial of aducanumab before it was stopped. He started receiving the drug again in August as part of a follow-up study, according to his wife Cynthia Flagg.

“He’s not 100 percent himself, but overall I’m not dealing with someone that needs to be led around or be in a care home,” Flagg said.

Aducanumab, an antibody designed to remove amyloid plaques from the brain – a strategy tried with many failed Alzheimer’s drugs – would reap billions of dollars in sales if approved.

Biogen, along with partner Eisai Co Ltd <4523.T>, is one of the last large drugmakers pursuing treatments for a disease that afflicts nearly 6 million Americans and millions more worldwide. Biogen estimates about 1.5 million people with early Alzheimer’s in the United States could be candidates for the drug.

Late last year, Biogen said one of its two pivotal studies of aducanumab showed a statistically significant benefit at slowing cognitive and functional decline in patients with early Alzheimer’s. A second trial failed to achieve that goal, but did show a benefit for a subset of patients who were given a high dose for at least 10 months.

In March, it opened a follow-up long-term safety study to 2,400 people who had

Read More